Haoxi Health Technology

Haoxi Health Technology provides online marketing and digital advertising solutions primarily to healthcare industry clients in China. The company specializes in short video and social media advertising, leveraging platforms like Douyin, WeChat, Toutiao, and Sina Weibo. It has demonstrated rapid revenue growth driven by the expansion of China's healthcare sector and increased demand for digital marketing[2][6]. The company recently expanded into livestreaming agency services targeting the medical aesthetics market[5].

Financially, Haoxi reported $23.5 million in revenue with $0.76 million net income for the six months ended December 31, 2023[6]. It completed its IPO on NASDAQ in January 2024 under the ticker HAO[2][8].

While it does not develop therapeutics or diagnostics itself, its business model supports healthcare providers' commercial efforts through advanced digital marketing technologies.

In April 2024 it signed an agreement to provide comprehensive advertising services to Jinan Yanling Biotechnology Co., Ltd.[6]

As of June 2025 it remains active but faces financial volatility and regulatory risks as noted by analysts following an $80M shelf registration filing[5].

Key executives have deep experience in both healthcare marketing and biotech sectors[7].

No evidence of direct drug development pipeline or clinical programs.